Jan-Olav Henck, PhD,
chief scientific officer
Jan-Olav Henck, PhD, chief scientific officer at Aptuit, discusses strategies and considerations in polymorph screening with Patricia Van Arnum, senior editor of Pharmaceutical Technology (Posted November 2011).
The company announced that an August 2016 FDA inspection of the company’s facility resulted in no form 483s.
This key bioprocessing segment is expecting continued growth.
Evonik’s parenteral drug delivery and commercial drug product manufacturing in Alabama passes EU GMP inspection.
FDA leaders insist that the decision to approve Sarepta’s Exondys (eteplirsen) should not be considered a model for future development of orphan drugs.
The new guidelines will address bioanalytical method validation and biopharmaceutics classification system-based biowaivers.
The agency awarded 21 new clinical trial research grants to boost the development of treatments for rare diseases.
Ingredients Insider Cynthia ChallenerThe Search for Practical and Economical Catalysts